3D Bioprinted Tumor-Stroma Models of Triple-Negative Breast Cancer Stem Cells for Preclinical Targeted Therapy Evaluation

Other authors

Institut Català de la Salut

[González-Callejo P] CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Spain. [García-Astrain C, Herrero-Ruiz A, Henriksen-Lacey M] CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Spain. Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain. [Seras-Franzoso J] Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain. Grup de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Abasolo I] Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain. Grup de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Bioquímica Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2024-06-06T05:47:14Z

2024-06-06T05:47:14Z

2024-05-29



Abstract

3D bioprinting; Cancer stem cells; Triple-negative breast cancer


Bioimpresión 3D; Células madre cancerosas; Cáncer de mama triple negativo


Bioimpressió 3D; Cèl·lules mare cancerígenes; Càncer de mama triple negatiu


Breast cancer stem cells (CSCs) play a pivotal role in therapy resistance and tumor relapse, emphasizing the need for reliable in vitro models that recapitulate the complexity of the CSC tumor microenvironment to accelerate drug discovery. We present a bioprinted breast CSC tumor-stroma model incorporating triple-negative breast CSCs (TNB-CSCs) and stromal cells (human breast fibroblasts), within a breast-derived decellularized extracellular matrix bioink. Comparison of molecular signatures in this model with different clinical subtypes of bioprinted tumor-stroma models unveils a unique molecular profile for artificial CSC tumor models. We additionally demonstrate that the model can recapitulate the invasive potential of TNB-CSC. Surface-enhanced Raman scattering imaging allowed us to monitor the invasive potential of tumor cells in deep z-axis planes, thereby overcoming the depth-imaging limitations of confocal fluorescence microscopy. As a proof-of-concept application, we conducted high-throughput drug testing analysis to assess the efficacy of CSC-targeted therapy in combination with conventional chemotherapeutic compounds. The results highlight the usefulness of tumor-stroma models as a promising drug-screening platform, providing insights into therapeutic efficacy against CSC populations resistant to conventional therapies.


Funding Sources Financial support was provided by the European Research Council (ERC-AdG-2017 #787510 4DBIOSERS and ERC-2023-POC #101138255 3DTUMOUR). C.G.A. thanks the Spanish State Research Agency for a Juan de la Cierva Incorporación Fellowship (FJCI-2016-28887). I.A. is grateful for the SGR grant from the Catalan Government (2021 SGR 1173). Figures were created using BioRender.

Document Type

Article


Published version

Language

English

Publisher

American Chemical Society

Related items

ACS Applied Materials & Interfaces;16(21)

https://doi.org/10.1021/acsami.4c04135

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)